The FDA Has Approved A New Indication For Merck's Prevymis (Letermovir) For Prophylaxis Of Cytomegalovirus (CMV) Disease In Adult Kidney Transplant Recipients At High Risk Following A Priority Review
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved a new indication for Merck's Prevymis (Letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk. Prevymis is an antiviral agent initially approved in 2017 for CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.
June 06, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's Prevymis receives FDA approval for a new indication, expanding its use for prophylaxis of CMV disease in high-risk adult kidney transplant recipients.
The FDA approval of a new indication for Merck's Prevymis expands its potential market and usage, which could lead to increased sales and revenue for the company. This positive news is likely to have a short-term positive impact on Merck's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100